The overarching goal of this review is to investigate how adiponectin signaling may ameliorate pathology associated with dystrophin deficiency through inflammatory-dependent and -independent mechanisms and to determine if current data supports their future progression to clinical trials. The gene discussed is ADIPOQ; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.